New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting ...
Jul 6, 2019
0
0
(HealthDay)—Survival odds for colorectal cancer may depend on which side of the colon the primary tumor develops, according to a study released Wednesday during a media briefing that previewed some of the research to be ...
May 20, 2016
0
2
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in ...
Jun 16, 2023
0
9
Massachusetts General Hospital (MGH) investigators have identified a potential mechanism behind the resistance that inevitably develops to cancer treatment with a combination of chemotherapy and antiangiogenic drugs. In a ...
Oct 12, 2016
0
1
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase ...
Jul 6, 2019
0
2
(HealthDay)—Expensive medications are being given far more often to elderly patients with metastatic colorectal cancer, but they offer almost no benefit, according to a study published online Feb. 19 in Medical Care.
Mar 11, 2016
0
2
Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond to immune checkpoint ...
Mar 21, 2019
0
7
In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan ...
Apr 15, 2016
0
129
These days, cancer researchers aim to design targeted and specific therapy – those that kill cancer but spare the surrounding tissue. Immunotoxins, which use cancer-targeted antibodies linked to deadly toxins such as ricin, ...
Sep 8, 2014
0
0
Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, ...
Jul 6, 2019
0
0
